Clinical Commander

Back to dossier
uro.uti.pediatric.v1PRODUCTION
uro.uti.pediatric.v1

Pediatric UTI (neonate / infant / older child / adolescent; VUR, recurrent, dysfunctional voiding)

urologyacutepediatricneonatal
Hard-required inputs
0 / 17
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Pediatric patient (neonate through adolescent) with possible UTI — age, sex, congenital anomaly status, dysfunctional voiding pattern, prior UTI history. <2 mo + fever → route to peds.febrile-infant.core.v1 for full sepsis workup; first UTI in male child → ALWAYS abnormal workup (AAP 2011)

Inputs
5
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (23)

AAP 2011 — renal + bladder ultrasound after first febrile UTI (2–24 mo) to rule out obstruction and anatomic anomaly

Uncircumcised male infants have ~10× UTI risk in first year vs circumcised; counsel parents in recurrent cases (AAP 2011)

Recurrent ≥3 / 12 mo or ≥2 febrile / 6 mo → DMSA + urology referral (AAP 2011)

Grade III–V → prophylaxis (RIVUR / PRIVENT) or surgical reimplantation; grade I–II usually conservative

PUV, UPJ obstruction, neurogenic bladder, duplex system → urology co-management; expanded empirics

Holding, encopresis, constipation → behavioural / bowel-bladder dysfunction; routes to uro.urinary-incontinence-eval.v1

Recent abx → resistance pattern shift; avoid prior agent (AAP 2011)

Age stratifies risk and workup intensity: <2 mo → full sepsis workup; 2–24 mo → AAP Bagga; >24 mo → similar to adult cystitis (AAP 2011 PMID 21873693)

Male UTI is uncommon and ALWAYS abnormal until proven otherwise (PUV, VUR); female anatomy more permissive (AAP 2011)

Children <2 yo (or non-toilet-trained) — catheter or SPA only (bag urine has false-positive rate too high for diagnosis) (AAP 2011)

Catheter culture ≥50,000 CFU/mL OR SPA ≥10,000 CFU/mL with pyuria — diagnostic threshold (AAP 2011)

Renal function for dose adjustment + AKI staging (KDIGO 2026)

Fever ≥38.0°C drives febrile-UTI pathway (admission threshold lower in <2 mo)

Hypotension → urosepsis ICU pathway (id.sepsis.peds.v1 + SCC 2026 pediatric)

Toxic / ill-appearing infant → admit + IV abx regardless of UA results

All pediatric dosing is weight-based (mg/kg/day) (AAP 2011)

Family-shared meds; allergy history; recent abx (AAP 2011)

AAP 2011 — VCUG only if recurrent febrile UTI OR abnormal US OR atypical organism; not first-line

On prophylaxis breakthrough → resistance pattern; switch agent (RIVUR)

Recent toilet training → behavioural UTI risk window

Leukocytosis / left shift → severity; thrombocytopenia → sepsis (pediatric SSC 2020)

CRP/PCT pediatric severity adjunct (panel.inflammation)

STAT in <2 mo + ill-appearing + admitted patients (peds.febrile-infant.core.v1)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (11)

11 need judgement
  • informationalsevereinfant_under_2mo_with_fever_workup
    Infant <2 mo with rectal temperature ≥38.0°C — FULL sepsis workup (CBC, CMP, UA via catheter / SPA, blood culture, LP) + IV abx (ampicillin + gentamicin) + admit; route to peds.febrile-infant.core.v1 (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecongenital_anomaly_UTI
    Known congenital anomaly (PUV, UPJ obstruction, neurogenic bladder, duplex system) + UTI — urology co-management; broader empirics until culture; consider imaging for obstruction (AUA pediatric)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefebrile_uti_2_to_24_mo
    Febrile child 2–24 mo without clear source — AAP 2011 Bagga criteria → catheter / SPA UA + culture; IV ceftriaxone if admitting OR oral cefixime / cefdinir if low-risk + reliable follow-up; renal + bladder US after first febrile UTI (AAP 2011 PMID 21873693)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefirst_uti_in_male
    First UTI in a male child of ANY age — ALWAYS abnormal until proven otherwise (posterior urethral valves / VUR workup); renal + bladder US + VCUG within 4–6 wk (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateVUR_grade_3_to_5_diagnosed
    Diagnosed vesicoureteral reflux grade III–V → continuous low-dose prophylaxis (TMP-SMX 2 mg/kg/day or nitrofurantoin 1–2 mg/kg/day qhs) × 6–12 mo OR surgical correction (RIVUR 2014 PMID 24795142; AAP 2011 PMID 21873693)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_pediatric_uti
    Recurrent pediatric UTI (≥3 in 12 mo OR ≥2 febrile in 6 mo) → DMSA scintigraphy for scarring + urology referral + reassess prophylaxis (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatebreakthrough_uti_on_prophylaxis
    Breakthrough UTI on continuous prophylaxis → switch agent per culture susceptibility + reassess prophylaxis decision (RIVUR; PRIVENT)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildafebrile_cystitis_older_child_adolescent
    Verbal child / adolescent with dysuria + frequency + urgency, afebrile — amoxicillin / cephalexin / TMP-SMX × 7–10 d (resistance pattern guides); similar to adult uncomplicated (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmilddysfunctional_voiding_uti
    Dysfunctional voiding / encopresis / constipation + UTI — bowel-bladder dysfunction pathway; route to uro.urinary-incontinence-eval.v1 for behavioural + laxative therapy (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildcircumcision_status_male_UTI_risk
    Uncircumcised male infant with recurrent UTI — counsel parents on circumcision risk/benefit (AAP 2012 — informed parental decision); ~10× UTI risk in first year vs circumcised
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildtoilet_training_associated_uti
    UTI during toilet-training period — behavioural transition; counsel scheduled voiding + hydration + bowel regularity; usually resolves with training maturation (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Pediatric UTI — age-tiered empiric (IV in <2 mo, IV ceftriaxone or oral cef in 2–24 mo, oral amoxicillin / cephalexin / TMP-SMX in older child) + VUR prophylaxis (TMP-SMX or nitrofurantoin low-dose) + AVOID FQ / tetracyclines <8 yo / sulfa <2 mo
axis: pediatric_uti_age_tiered_and_VUR_prophylaxisstep 1 - STEP 1 — <2 mo with fever → FULL sepsis workup + IV ampicillin + gentamicin OR IV ampicillin + cefotaxime (AAP / peds.febrile-infant.core.v1)
Selected step "STEP 1 — <2 mo with fever → FULL sepsis workup + IV ampicillin + gentamicin OR IV ampicillin + cefotaxime (AAP / peds.febrile-infant.core.v1)" — Infant <2 mo with rectal temperature ≥38.0°C
  • ampicillin
    first line
    aminopenicillin
    50–100 mg/kg/dose IV q6–8h (neonatal dosing) • IV • q6–8h
    triggers: infant_under_2mo_fever, sepsis_workup_pathway
    Pediatric neonatal sepsis empiric — Listeria + Enterococcus coverage (peds.febrile-infant.core.v1)
    rxcui 733
  • gentamicin
    first line
    aminoglycoside
    4–5 mg/kg/dose IV q24h (neonatal — adjust per gestational age) • IV • q24h
    triggers: infant_under_2mo_fever, gram_negative_coverage
    Pediatric neonatal sepsis empiric — gram-negative coverage; renal function monitoring (peds.febrile-infant.core.v1)
    rxcui 1596450
  • cefotaxime
    first line
    cephalosporin_3rd_gen
    50 mg/kg/dose IV q8h (neonatal) • IV • q8h
    triggers: infant_under_2mo_fever, gent_avoid, meningitis_concern
    Alternative to gent — better CNS penetration if meningitis concern (AAP)
    rxcui 2186

outpatient playbook — drug actions (6)

  1. 1. cefixime (febrile UTI 2–24 mo, low-risk PO)
    8 mg/kg/day PO once daily × 10–14 d • PO • once daily
    trigger: Febrile UTI 2–24 mo, PO-tolerant, reliable follow-up
    AAP 2011 oral first-line
  2. 2. cefdinir (febrile UTI alternative)
    14 mg/kg/day PO q12h × 10 d • PO • q12h
    trigger: cefixime alternative
    AAP 2011 oral alternative; red-stool warning
  3. 3. amoxicillin (afebrile cystitis older child)
    25–50 mg/kg/day PO q8h × 7–10 d • PO • q8h
    trigger: Afebrile cystitis, susceptible E. coli, no prior exposure
    AAP 2011
  4. 4. cephalexin (afebrile alternative)
    25–50 mg/kg/day PO q6h × 7–10 d • PO • q6h
    trigger: amoxicillin alternative
    AAP 2011
  5. 5. TMP-SMX (afebrile if susceptible)
    8 mg/kg/day (TMP) PO q12h × 7–10 d • PO • q12h
    trigger: Local resistance <20% + age >2 mo + no sulfa allergy
    AAP 2011
  6. 6. TMP-SMX (VUR prophylaxis low-dose)
    2 mg/kg/day (TMP) PO qhs × 6–12 mo • PO • once daily
    trigger: Known VUR grade III–V
    RIVUR 2014 (PMID 24795142)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Infant <2 mo with rectal temperature ≥38.0°C — UTI is on the differential; FULL workup pathway (peds.febrile-infant.core.v1) (AAP 2011); Febrile child 2–24 mo without clear source — UA + culture per AAP 2011 Bagga criteria (PMID 21873693); Verbal child / adolescent with dysuria + frequency + urgency (similar to adult uncomplicated cystitis).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Pediatric UTI (neonate / infant / older child / adolescent; VUR, recurrent, dysfunctional voiding)** (uro.uti.pediatric.v1).
Phenotype framing: Pediatric UTI vs viral illness vs occult bacteremia vs vulvovaginitis (girls) vs balanitis (boys) vs appendicitis (often presents atypically with urinary symptoms in children) vs nephrolithiasis vs encopresis-related (AAP 2011)
Scope: Pediatric patient (neonate through adolescent) with possible UTI — age, sex, congenital anomaly status, dysfunctional voiding pattern, prior UTI history. <2 mo + fever → route to peds.febrile-infant.core.v1 for full sepsis workup; first UTI in male child → ALWAYS abnormal workup (AAP 2011)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Pediatric UTI — age-tiered empiric (IV in <2 mo, IV ceftriaxone or oral cef in 2–24 mo, oral amoxicillin / cephalexin / TMP-SMX in older child) + VUR prophylaxis (TMP-SMX or nitrofurantoin low-dose) + AVOID FQ / tetracyclines <8 yo / sulfa <2 mo** — step "STEP 1 — <2 mo with fever → FULL sepsis workup + IV ampicillin + gentamicin OR IV ampicillin + cefotaxime (AAP / peds.febrile-infant.core.v1)".
1. ampicillin 50–100 mg/kg/dose IV q6–8h (neonatal dosing) IV q6–8h (aminopenicillin, first line) — Pediatric neonatal sepsis empiric — Listeria + Enterococcus coverage (peds.febrile-infant.core.v1)
2. gentamicin 4–5 mg/kg/dose IV q24h (neonatal — adjust per gestational age) IV q24h (aminoglycoside, first line) — Pediatric neonatal sepsis empiric — gram-negative coverage; renal function monitoring (peds.febrile-infant.core.v1)
3. cefotaxime 50 mg/kg/dose IV q8h (neonatal) IV q8h (cephalosporin_3rd_gen, first line) — Alternative to gent — better CNS penetration if meningitis concern (AAP)

Setting playbook (outpatient) — Catheter / SPA urine collection for <2 yo; UA + culture; AAP 2011 algorithm: oral cefixime / cefdinir for low-risk febrile 2–24 mo OR amoxicillin / cephalexin / TMP-SMX for afebrile older child; renal + bladder US after first febrile UTI; reliable 24–48 h follow-up (AAP 2011)
4. cefixime (febrile UTI 2–24 mo, low-risk PO) 8 mg/kg/day PO once daily × 10–14 d PO once daily — Febrile UTI 2–24 mo, PO-tolerant, reliable follow-up (AAP 2011 oral first-line)
5. cefdinir (febrile UTI alternative) 14 mg/kg/day PO q12h × 10 d PO q12h — cefixime alternative (AAP 2011 oral alternative; red-stool warning)
6. amoxicillin (afebrile cystitis older child) 25–50 mg/kg/day PO q8h × 7–10 d PO q8h — Afebrile cystitis, susceptible E. coli, no prior exposure (AAP 2011)
7. cephalexin (afebrile alternative) 25–50 mg/kg/day PO q6h × 7–10 d PO q6h — amoxicillin alternative (AAP 2011)
8. TMP-SMX (afebrile if susceptible) 8 mg/kg/day (TMP) PO q12h × 7–10 d PO q12h — Local resistance <20% + age >2 mo + no sulfa allergy (AAP 2011)
9. TMP-SMX (VUR prophylaxis low-dose) 2 mg/kg/day (TMP) PO qhs × 6–12 mo PO once daily — Known VUR grade III–V (RIVUR 2014 (PMID 24795142))

Non-pharmacologic actions:
- Patient + caregiver education — return precautions, fever, vomiting, no improvement at 48 h
- Renal + bladder US scheduled within 2 wk if first febrile UTI 2–24 mo
- Urology referral if first UTI in male / VUR grade III–V / recurrent / anatomic anomaly
- Bowel-bladder dysfunction pathway (route to uro.urinary-incontinence-eval.v1) if dysfunctional voiding / constipation
- Circumcision discussion if recurrent in uncircumcised male infant
- 24–48 h follow-up call

AVOID / contraindication checks:
- Fluoroquinolones_AVOID_in_children_cartilage_FDA_default_avoid (FDA / AAP 2011)
- Tetracyclines_AVOID_under_8yo_permanent_tooth_discoloration (AAP)
- Sulfa_AVOID_under_2mo_kernicterus_bilirubin_displacement (AAP)
- Nitrofurantoin_AVOID_in_pyelonephritis_no_renal_tissue_penetration (AAP 2011)
- Nitrofurantoin_AVOID_under_1mo_G6PD_hemolysis (FDA / AAP)
- Bag_urine_NOT_diagnostic_in_under_2yo_use_catheter_or_SPA (AAP 2011)
- Routine_VCUG_NOT_indicated_after_first_febrile_UTI_only_if_atypical_or_recurrent_or_abnormal_US (AAP 2011)
- Gentamicin_renal_and_ototoxicity_monitor_levels_pediatric (FDA)
- Ceftriaxone_AVOID_in_neonates_with_hyperbilirubinemia_displaces_bilirubin (FDA)
- Weight_based_dosing_mandatory_in_all_pediatric_prescribing (AAP)
- Asymptomatic_bacteriuria_DO_NOT_TREAT_in_children_except_pre_procedure (AAP)
- Circumcision_discussion_for_recurrent_uncircumcised_male_infants_balanced_counseling (AAP 2012)
- VUR_grade_3_to_5_prophylaxis_or_surgery_decision_with_urology (RIVUR; PRIVENT)

Monitoring

Regimen monitoring:
- symptom resolution by 48 to 72h (AAP 2011)
- urine culture results at 24 to 48h adjust per susceptibility (AAP 2011)
- renal function and gent levels in neonates (FDA)
- renal bladder US within 2 weeks after first febrile UTI 2 to 24mo (AAP 2011)
- VCUG only if atypical or recurrent febrile or abnormal US (AAP 2011)
- DMSA scintigraphy if recurrent UTI ge 3 in 12mo or ge 2 febrile in 6mo (AAP)
- reassess prophylaxis annually RIVUR PRIVENT (RIVUR 2014; PRIVENT 2010)
- growth and renal function in children with known VUR or anatomic anomaly (AUA pediatric)

Setting (outpatient) monitoring:
- Symptom resolution at 48–72 h (AAP 2011)
- Culture results at 24–48 h — tailor empiric
- Treatment failure → admit

Follow-up plan: Renal + bladder US in 2–24 mo after first febrile UTI; VCUG if atypical / recurrent / abnormal US; DMSA if recurrent; urology referral if VUR / anatomic anomaly / male / recurrent; prophylaxis discussion (RIVUR / PRIVENT); dysfunctional voiding pathway (uro.urinary-incontinence-eval.v1); circumcision discussion in recurrent uncircumcised (AAP 2011)
- Close-out criterion: follow-up + imaging plan documented

Monitoring phase: Symptom resolution at 48–72 h; culture results 24–48 h → tailor; recheck after course; imaging follow-up per AAP algorithm

Disposition

Current setting: outpatient — Catheter / SPA urine collection for <2 yo; UA + culture; AAP 2011 algorithm: oral cefixime / cefdinir for low-risk febrile 2–24 mo OR amoxicillin / cephalexin / TMP-SMX for afebrile older child; renal + bladder US after first febrile UTI; reliable 24–48 h follow-up (AAP 2011)

Disposition criteria:
- Discharge with oral abx + 24–48 h follow-up + return precautions (AAP 2011)
- Admit if <2 mo / ill / non-PO / failed outpatient (AAP 2011)

Escalation triggers (move to higher acuity):
- Treatment failure at 48–72 h → admit
- Vomiting / non-PO → admit
- Ill-appearing at follow-up → ED

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] Infant <2 mo with rectal temperature ≥38.0°C — FULL sepsis workup (CBC, CMP, UA via catheter / SPA, blood culture, LP) + IV abx (ampicillin + gentamicin) + admit; route to peds.febrile-infant.core.v1 (AAP 2011)
- [SEVERE] Known congenital anomaly (PUV, UPJ obstruction, neurogenic bladder, duplex system) + UTI — urology co-management; broader empirics until culture; consider imaging for obstruction (AUA pediatric)
- [MODERATE] Febrile child 2–24 mo without clear source — AAP 2011 Bagga criteria → catheter / SPA UA + culture; IV ceftriaxone if admitting OR oral cefixime / cefdinir if low-risk + reliable follow-up; renal + bladder US after first febrile UTI (AAP 2011 PMID 21873693)

Citations

- AAP 2011 UTI Clinical Practice Guideline (Roberts) + AAP 2016 reaffirmation + RIVUR antimicrobial-prophylaxis VUR trial 2014 + IDSA Asymptomatic Bacteriuria 2019 (do-not-treat ASB) [PMID:21873693](https://pubmed.ncbi.nlm.nih.gov/21873693/)
- Cited evidence (PMID 27940735) [PMID:27940735](https://pubmed.ncbi.nlm.nih.gov/27940735/)
- Cited evidence (PMID 24795142) [PMID:24795142](https://pubmed.ncbi.nlm.nih.gov/24795142/)
- Cited evidence (PMID 30895288) [PMID:30895288](https://pubmed.ncbi.nlm.nih.gov/30895288/)

Last reconciled with current guidelines: 2026-05-22.
References
  • AAP 2011 UTI Clinical Practice Guideline (Roberts) + AAP 2016 reaffirmation + RIVUR antimicrobial-prophylaxis VUR trial 2014 + IDSA Asymptomatic Bacteriuria 2019 (do-not-treat ASB) — PMID:21873693
  • Cited evidence (PMID 27940735) — PMID:27940735
  • Cited evidence (PMID 24795142) — PMID:24795142
  • Cited evidence (PMID 30895288) — PMID:30895288